| pubmed-article:2217831 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2217831 | lifeskim:mentions | umls-concept:C0150097 | lld:lifeskim |
| pubmed-article:2217831 | lifeskim:mentions | umls-concept:C0026032 | lld:lifeskim |
| pubmed-article:2217831 | lifeskim:mentions | umls-concept:C0007785 | lld:lifeskim |
| pubmed-article:2217831 | lifeskim:mentions | umls-concept:C0023779 | lld:lifeskim |
| pubmed-article:2217831 | lifeskim:mentions | umls-concept:C0033567 | lld:lifeskim |
| pubmed-article:2217831 | lifeskim:mentions | umls-concept:C1527240 | lld:lifeskim |
| pubmed-article:2217831 | lifeskim:mentions | umls-concept:C0439611 | lld:lifeskim |
| pubmed-article:2217831 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:2217831 | pubmed:dateCreated | 1990-11-14 | lld:pubmed |
| pubmed-article:2217831 | pubmed:abstractText | Lipo-PGI2 is a drug preparation of a PGI2 analogue (isocarbacyclin methylester) which is incorporated into lipid microspheres with a diameter of 0.2 mu. Lipo-PGI2 has been shown to accumulate at the vascular wall, particularly those of arteriosclerotic lesions, and it has a much stronger inhibitory activity on platelet aggregation than free isocarbacyclin. In this study, a preliminary double-blind cross over trial of lipo-PGI2 in cerebral infarction was carried out. Seventeen patients with chronic cerebral infarction received 2 micrograms of lipo-PGI2 and placebo daily for one week each in a cross-over double blind test. A significant improvement was noted for lipo-PGI2 compared with placebo in the overall improvement in neurological and mental symptoms (p less than 0.01). The patient's preference also indicated the effectiveness of lipo-PGI2 (p less than 0.05). Adverse reactions were noted in 3 patients receiving placebo, but not in any receiving lipo-PGI2. These results show that lipo-PGI2 at a very low dose would be beneficial as a treatment for relieving the clinical symptoms of chronic cerebral infarction and that lipid microspheres are a useful drug carrier for PGI2 analogue therapy. | lld:pubmed |
| pubmed-article:2217831 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2217831 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2217831 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2217831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2217831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2217831 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2217831 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2217831 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:2217831 | pubmed:issn | 0090-6980 | lld:pubmed |
| pubmed-article:2217831 | pubmed:author | pubmed-author:HoshiKK | lld:pubmed |
| pubmed-article:2217831 | pubmed:author | pubmed-author:MizushimaYY | lld:pubmed |
| pubmed-article:2217831 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2217831 | pubmed:volume | 40 | lld:pubmed |
| pubmed-article:2217831 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2217831 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2217831 | pubmed:pagination | 155-64 | lld:pubmed |
| pubmed-article:2217831 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:2217831 | pubmed:meshHeading | pubmed-meshheading:2217831-... | lld:pubmed |
| pubmed-article:2217831 | pubmed:meshHeading | pubmed-meshheading:2217831-... | lld:pubmed |
| pubmed-article:2217831 | pubmed:meshHeading | pubmed-meshheading:2217831-... | lld:pubmed |
| pubmed-article:2217831 | pubmed:meshHeading | pubmed-meshheading:2217831-... | lld:pubmed |
| pubmed-article:2217831 | pubmed:meshHeading | pubmed-meshheading:2217831-... | lld:pubmed |
| pubmed-article:2217831 | pubmed:meshHeading | pubmed-meshheading:2217831-... | lld:pubmed |
| pubmed-article:2217831 | pubmed:meshHeading | pubmed-meshheading:2217831-... | lld:pubmed |
| pubmed-article:2217831 | pubmed:meshHeading | pubmed-meshheading:2217831-... | lld:pubmed |
| pubmed-article:2217831 | pubmed:meshHeading | pubmed-meshheading:2217831-... | lld:pubmed |
| pubmed-article:2217831 | pubmed:meshHeading | pubmed-meshheading:2217831-... | lld:pubmed |
| pubmed-article:2217831 | pubmed:meshHeading | pubmed-meshheading:2217831-... | lld:pubmed |
| pubmed-article:2217831 | pubmed:meshHeading | pubmed-meshheading:2217831-... | lld:pubmed |
| pubmed-article:2217831 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2217831 | pubmed:articleTitle | A preliminary double-blind cross-over trial of lipo-PGI2, a prostacyclin derivative incorporated in lipid microspheres, in cerebral infarction. | lld:pubmed |
| pubmed-article:2217831 | pubmed:affiliation | Department of Internal Medicine, St. Marianna University, School of Medicine, Kawasaki, Japan. | lld:pubmed |
| pubmed-article:2217831 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2217831 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2217831 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2217831 | lld:pubmed |
